Educational research platform

Before you begin

Welcome to Peptide Relay

Explore source-linked research, practical tools, and Community Intelligence with evidence, interpretation, and personal experience kept clearly separated.

Please confirm
Choose how you enter RelayYou can change your mind and create a workspace later.

No account is required for the Research Library, Learn, Compare, Stack Explorer, Community, or Tools. A free workspace is only required for private features such as My Relay, Protocol Tracker, saved work, following compounds, and managing Community Experiences.

Peptide Relay status

Public Alpha

v0.9.0

Building Relay with the community.

Relay is now feature-complete and has entered its first Public Alpha.

From this point forward, improvements are driven by real-world usage, community feedback, analytics, and research rather than internal feature planning.

Thank you for helping shape Relay.

What's NewWhat shipped in the current release
v0.9.0 — Public AlphaJuly 2026

Research Library

Thirty-five source-traceable compound and blend profiles with plain-English summaries, detailed science, evidence context, timelines, and references.

Learn

Peptide 101 and seven cornerstone guides for reading studies, mechanisms, evidence strength, personal experiences, and research uncertainty.

Compare

Side-by-side research context with shared, different, and unknown states—without inventing head-to-head conclusions.

Stack Explorer

Multi-compound pathway and evidence analysis with exact-combination limits and unanswered questions kept visible.

Community Experiences

Anonymous structured Experience Reports, separate story consent, verified follow-ups, moderation, and privacy-thresholded Community Intelligence.

Protocol Tracker

Private schedules, administrations, reflections, measurements, inventory, imports, lifecycle controls, and reconstitution support.

Reconstitution Hub

Single-compound and blend calculations, visual syringe and vial interpretation, reference marks, and private saved workspaces.

Relay-wide Search

One alias-aware search experience across public research and signed-in workspace destinations.

Mobile Optimization

Reliable touch selection, tighter information density, responsive tables and tabs, and mobile-first workflow refinement.

Motion System

One restrained motion language that explains state changes and respects reduced-motion preferences.

Platform Improvements

Database contract auditing, private-route indexing boundaries, public-route smoke tests, clearer recovery messages, and stronger protection against false-success writes.

RoadmapDirection without promised timelines

Roadmap items describe current direction. Public Alpha evidence may change their order or scope.

Now
  • Community growth
  • Bug fixes
  • UX improvements
  • Content expansion
Next
  • Relay+ features
  • Additional research tools
  • Expanded compound library
Future
  • Relay AI
  • Native iPhone app (planned)
  • Native Android app (planned)
Known IssuesMeaningful issues users may encounter
No known critical issues at this time.

Newly confirmed issues will appear here when they meaningfully affect the public experience.

FeedbackHelp improve the next release

Found a bug?Have a suggestion?

Submit feedback to help improve Relay
Version HistoryPublic releases and milestones
v0.9.0

Public Alpha

The first feature-complete public release candidate for Peptide Relay.

Released July 2026

Last updated July 2026 · Updated with every public release.

Peptide 101 · Guide 4 of 6

How strong is the evidence?

Understand what different study types can answer—and why no label replaces careful appraisal.

The simple answer

Evidence is strongest for a specific claim when research tests that claim directly, in a relevant population, with methods that reduce bias—and when the result is precise, consistent, and supported by more than one study.

Human, animal, cell, and mechanistic evidence answer different questions. Study type matters, but it is not an automatic score: a poorly designed human study can be less informative than a careful study answering a narrower question.

4 min read Reviewed July 28, 2026 5 sources

Begin with the exact claim

Evidence does not have one strength in the abstract. It is strong or weak in relation to a specific question.

A cell experiment may directly answer whether a compound activates a receptor in that test system. The same experiment is indirect evidence for a claim about a meaningful health outcome in people.

Different study types answer different questions

Mechanistic work asks how an effect might occur. In vitro research studies cells, molecules, or tissues outside a living organism. In vivo animal research examines effects in a whole nonhuman organism. Clinical research studies people.

Each step can add useful information. FDA explicitly notes that preclinical research can answer basic questions about toxicity and biological activity, but it is not a substitute for studying how a drug interacts with the human body.

Human evidence still needs appraisal

Observational studies examine what happens without randomly assigning the exposure. They can reveal associations and may be valuable when randomization is impossible or when studying uncommon or longer-term events.

Randomized trials assign participants to groups by chance. When designed and conducted well, randomization helps reduce confounding—other differences between groups that could explain the outcome. Randomized does not mean flawless; missing data, selective reporting, small samples, short duration, and other problems can still weaken confidence.

Look beyond a single study

Confidence grows when multiple relevant studies point in the same direction, use sound methods, measure outcomes that matter, and produce estimates precise enough to be useful.

A result can be statistically significant and still be small, uncertain in practice, or limited to a narrow population. Relay therefore keeps population, comparison, outcome, duration, and limitations attached to the finding.

Closer to a human outcome—not an automatic quality score

MechanismWhy might an effect be plausible?
Cell or animalWhat happens in a model?
Human observationWhat is associated in people?
Controlled human testWhat changes under a direct comparison?
Each layer can be rigorous or weak. The right question is whether the evidence directly and reliably supports the claim being made.

What this can—and cannot—tell us

What it can tell us

  • How directly a study addresses a specific claim.
  • Which biases and limitations may change confidence.
  • Whether findings are consistent, precise, and applicable to the population of interest.

What it cannot establish alone

  • That every randomized trial is automatically trustworthy.
  • That an animal or cell result will produce the same outcome in people.
  • That one positive study settles every question about benefits, harms, or long-term effects.
Go deeperOptional · about 1 minute

Why Relay avoids a single evidence score

Evidence appraisal involves several dimensions: risk of bias, directness, consistency, precision, and the possibility of missing or selectively reported evidence. Compressing these into one unexplained number can conceal the reason confidence is limited.

Relay instead shows the evidence type and the limitation that matters. A user can see whether uncertainty comes from indirect animal evidence, a small sample, conflicting results, a short study, or another specific problem.

Why observational evidence still matters

Cochrane notes that some intervention questions cannot or are unlikely to be answered by randomized trials. Nonrandomized evidence may be necessary, especially for population-level interventions or some harms.

The tradeoff is greater concern about confounding and selection bias. Useful does not mean equivalent; the study must be interpreted for the question it can reasonably answer.

The takeaway

If you only remember one thing from this guide:

The strongest evidence is not the fanciest study label—it is evidence that directly and reliably answers the specific question.

Sources and support5 sources
  1. Step 2: Preclinical Research U.S. Food and Drug Administration

    Describes in vitro and in vivo preclinical research and the questions it addresses before human testing.

  2. Step 3: Clinical Research U.S. Food and Drug Administration

    States that preclinical research is not a substitute for studies in people and outlines core clinical-trial design questions.

  3. Explains confounding, randomization, and the need to assess bias in randomized-trial results.

  4. Explains both the uses of nonrandomized studies and their greater potential for confounding and bias.

  5. Supports multidimensional appraisal using domains such as risk of bias, directness, consistency, and precision.